Record share trading at Hamak Gold

3

Liberia-focused gold explorer Hamak Gold (LON: HAMA) was the best performer on Monday after it reported positive results from its first drill hole at the Nimba licence. There were 1.34 million shares traded on the day, which is treble the number traded on the previous record day.

The share price jumped 60% to 12p. Hamak Gold joined the standard list on 1 March when it raised £955,000 at 10p a share. This is the first time the share price has been above the placing price since March.

British Virgin Islands-registered Hamak Gold’s main assets are two gold licences in Liberia that cover 1,752 square kilometres and it has the option to acquire fiver other licences. The Nimba licence is next to the border and near to the Ity gold mine in the Ivory Coast. The Gozohn licence has significant gold diggings and is near to the Kokya mine in the centre of the country.

The drill hole at the Ziatoyah prospect intersected 20 metres at 7g/t. This suggests that there could be a significant mineralised system that is similar to the one at the Ity gold mine.

FTSE 100 dips ahead of key central bank decisions

Traders were positioning for busy week of central bank meetings on Monday as the FTSE 100 slipped 0.3% to 7,448 shortly after lunch.

Markets were bracing for interest rate decisions from the Federal Reserve on Wednesday, and the ECB and Bank of England on Thursday.

The announcements will mark the end of a year punctuated by soaring inflation and a central bank response that has threatened the health of the global economy.

“Caution is in the air in financial markets ahead of a series of crunch central bank meetings around the world this week, with yet more interest rate hikes set to be unwrapped as inflation remains stubborn,” said Susannah Streeter, senior investment and markets analyst, Hargreaves Lansdown.

The Federal Reserve is expected to hike rates 50 bps to 4.5% which would represent a step back from the 75 bps hike last time round.

Economists predict the Bank of England will raise rates by 50 bps to 3.5% and the consensus also points to a 50 bps hike by the ECB.

2023 Interest Rates

Higher rates are largely priced into markets and investors will focus on the accompanying statements and press conferences for further insight into how central banks plan to adjust rates in the early months of 2023.

Recent comments from the Fed suggest a pivot could be around the corner. Indeed, if they are to hike by 50 bps, it would mark a slowing in pace of rate hikes.

The economic backdrop in the US is still not at a point that would warrant keeping rates as they are, given the persistently high level of inflation.

The Bank of England will have to take into consideration a 0.3% GDP contraction between July and October, despite a better than expected 0.5% increase in October.

“October’s bounce back was expected, and the fact the growth was a little more enthusiastic than economists had anticipated is welcome. But this is just an aside – the story is unchanged, the economy is still shrinking and recession feels inevitable,” said Danni Hewson, AJ Bell financial analyst.

The threat of a downturn was evident in the FTSE 100’s consumer-facing stocks with JD Sports, Sainsbury’s, Ocado and Kingfisher among the top fallers.

Hiousebuilders were also weaker, as were global cyclical sectors such as the miners and oil majors.

RBC Wealth Management look to defensive European equities in 2023

RBC Wealth Management have warned of possible downside in European equities in 2023 but highlighted favourable valuations as a mitigating factor for the region.

RBC Wealth Management’s outlook for 2023 struck a cautious tone and said they see an opportunity in positioning towards defensive sectors and companies with a global presence.

Overall, RBC said they were underweight European equities but suggested a discount to US stocks and low valuations have already accounted for a European recession.

“We continue to recommend an Underweight position in European equities given the prevailing uncertainties. However, we acknowledge that the long list of downside risks is partly reflected in sharply discounted valuations and extreme investor caution,” said Thomas McGarrity, Head of Equities at RBC Wealth Management.

“Based on a forward 12-month price-to-earnings (P/E) ratio of 12.9x, the MSCI Europe ex UK Index is trading at a discount to its 10-year median of around 14.5x. On a relative basis, the discount to U.S. equities is much steeper than typical, even taking into account sector differences.

“We continue to prefer defensive sectors over cyclicals, and maintain our bias for quality, globally diversified companies that possess strong pricing power. In particular, we see opportunities in companies which are global leaders within the pharmaceuticals, technology, luxury, and capital goods industries. We are also beginning to see select opportunities in deeply discounted cyclicals where valuations already appear to price in the prospect of a European recession, particularly in sectors such as Industrials and Materials.”

Europe is being particularly heavily hit by energy prices and domestic economies are facing a tough start to the year. This would justify the defensive positioning going into 2023.

However, despite the challenging outlook, RBC argue much of the bad news is largely priced in, and the current valuations are attractive enough to take a measured approach to cyclical names.

Power Metal Resources Q&A with Paul Johnson

The UK Investor Magazine was delighted to welcome Paul Johnson back to the Podcast to answer questions from investors.

Paul presented at the UK Investor Magazine Virtual Investor Conference 7th December and due to the high volume of investor questions at the event, we were unable to deliver all the questions to Paul.

This Podcast will address those questions.

Watch the full Power Metal Resources Virtual Investor Presentation here

AIM movers: RUA Life Sciences share price gains heart and Engage XR contract delays

5

The RUA Life Sciences (LON: RUA) share price has perked up following its interim results. Revenues grew by two-thirds to £917,000 and the medical devices developer had net cash of £2.51m at the end of September 2022. Preparations are underway for clinical trial for large bore vascular grafts and a decision on which prototype aortic heart valve is better should be made soon. The share price has risen 21.2% to 40p, which is the highest it has been for two months.

Velocys (LON: VLS) has been awarded two UK government grants. The larger one is a £27m grant for the Altato sustainable aviation fuel project in Immingham. This is being developed in partnership with BA. Velocys has to obtain matching funding from the private sector. Velocys will contribute up to £8m. A further £2.5m grant is for a new e-fuels project to make aviation fuel from carbon dioxide and hydrogen. The share price is 17.1% higher at 5.15p.

Oriole Resources (LON: ORR) has published a maiden JORC resource for the Bibemi gold project in Cameroon. The pit-constrained resource is estimated to be 4.3 million tonnes grading 2.19/t gold equating to 305,000 ounces. There could be up to 148,000 of additional gold in other resource blocks. The share price moved 13.6% ahead at 0.125p.

Artemis Resources (LON: ARV) says that drilling at the Paterson Central project in Western Australia reveals that the Apollo copper gold target is one part of a 1.5km magnetic regional anomaly. It is a similar structure to the nearby Havieron deposit. The share price rose 8.62% to 1.575p.

Engage XR (LON: EXR) warns that the fourth quarter has been slower than expected and 2022 revenues will be below €4m, rather than the previously forecast €4.9m. The extended reality technology developer says customers have delayed contract decisions. Net cash should be €1.9m at the end of 2022. Cost savings are being considered. The share price divided 44.2% on the news.

Capital Metals (LON: CMET) shares slumped by 42.1% to 2.75p following the receipt of a notice from the Sri Lanka Geological Surveys and Mines Bureau (GSMB) concerning the Eastern Minerals project. This notice concerns the ownership structure of the mineral sands project, which has not obtained approval from the authorities. That means the mining licences have been temporarily suspended. Changes to the GSMB management could delay the resolution of this problem.

Weak buyer confidence has prompted housebuilder Springfield Properties (LON: SPR) to temper its expectations for 2022-23 and next year. Revenues will still grow, helped by the recent acquisition, but increasing building costs will hit margins. The six months to November 2022 will not be as affected, but it will show through in the second half. The full year pre-tax profit forecast has been cut from £27.5m to £17m and the expected dividend has been reduced to 4.6p a share, down from 6.2p a share. The share price is 14.4% lower at 77p.

Poolbeg Pharma (LON: POLB) says that initial data from the 36 volunteer phase 1b challenge study with potential flu treatment POLB001 shows it is safe and well tolerated. Efficacy data should be available in the middle of 2023. Partnership discussions are ongoing. Even so, the share price fell 6.92% to 7.4p.

Coral Products – very impressive first half leads expectations of even better full year results

The last couple of years have seen quite a fundamental change in this Wythenshawe, Manchester-based group’s profile. 

Strategically it has acquired four new subsidiaries this year, at a cost of some £11.3m plus earn-outs.

But then change has been a way of life for £16m capitalised Coral Products (LON:CRU).

The interim results for the six months to end October clearly identify that the group has been investing in growth, both organically and through acquisition.

The big change is now on its way.

The business today

From its base in 1989, when it was serving the VHS market with a wide range of video cassette cases, the company listed in 1995 and switched to AIM in 2011.

Today Coral Products is a manufacturer and distributor of plastic products supplied into a diverse range of sectors. As a group of seven companies, it has extensive capabilities within profile, tube and sheet extrusion, injection moulding, vacuum forming, butt fusion, mirror welding, fabrication, and assembly. 

The seven subsidiaries

Tatra Rotalac is a leading plastic extrusions manufacturer providing custom extrusions, PVC profiles and injection mouldings for the building, telecoms, aerospace and rail sectors.

Global One Pak is a leading provider of own designed lotion pumps, closures and trigger sprayers, supplier to many well-known brands like Tesco, Asda-Walmart, M&S, and WD40.

Customised Packaging specialises in the manufacturing of plastic products using thermoforming and sheet extrusion technology.

Film & Foil Solutions is one of the UK’s largest converters and stockists of flexible film packaging films, print lamination films and speciality plastics, paper and aluminium foils.

Alma Products specialises in extrusion, thermoforming and container printing.

Manplas provides a custom manufacturing service for the production of vacuum-formed components and sheet plastic parts. 

Ecodeck recycles 10,000 tonnes of waste plastic per annum into sustainable and environmentally eco-friendlygarden and landscape construction products.

Ready to attract institutional investors

With some 97.6m shares in issue, Executive Chairman Jo Grimmond holds 7.66% of the equity, while other directors hold 6.78%.

Professional investors include Lombard International Assurance (5.71%), Diverse Income Trust (2.90%), Peter Gyllenhammar AB (2.80%), and Rights & Issues Investment Trust (2.38%).

Two private investors have notable holdings – John Wright (5.84%) and Ian Hillman (5.76%).

As this group builds up, I would expect it to become more attractive to smaller company fund managers.

The interims

The half-time results reported that the group’s sales had risen 147.9% to £17.6m, while its reported pre-tax profits put on 75.3% to £894,000. Its underlying EBITDA was 85.5% better at £1.88m, with underlying earnings put on 44.4% to 1.17p per share. The interim dividend was unaltered at 0.50p per share.

As part of its capital expenditure programme the group has committed £2.5m for new injection moulding machines, specific tooling and it has reconfigured some 5,000 sq.ft of warehouse space into extra manufacturing capacity.

Group property has been revalued to £3.2m, while net cash at the interim stage was £3.8m, showing an overall strong net asset position.

The group has fixed energy costs until 2025, while margin improvements should be seen in the second half.

Executive Chairman Joe Grimmond stated that: “These excellent results reflect our ongoing investment in future growth. Our objective is to build a specialist UK plastics business of scale, targeting profitable, high-demand sectors. We aim to drive growth both organically and via acquisitions, whilst maintaining our commitment to sustainable objectives……Like all businesses, we are mindful of the challenging economic environment, nevertheless, we believe Coral is in a good position going forward and we have yet to show the full benefit of our investments to date.”

Analyst Opinion – ‘fair value’ 21.6p a share

Edward Stacey at Cenkos Securities rates the group’s shares as a Buy.

His estimates for the current year to end April are for revenues of £34.6m (£14.4m), with adjusted pre-tax profits of £1.7m (£1.3m), lifting earnings up to 2.1p (1.5p) and a dividend of 1.2p (1.1p) per share.

For the coming year he sees £41.9m sales, £2.3m profits, 2.5p earnings and 1.3p of dividend per share.

Conclusion – I see them touching 25p in 2023

After speaking to boss Jo Grimmond at length on these figures I am convinced that he has ‘shaped’ up his group very well to grow over the next few years.

As investor interest builds up gradually ‘smallco funds’ will get aboard, taking the equity up to considerably more flexible ratings.

The shares, now at just 17.5p, are clearly heading higher, with 25p being an easy level at which to aim in 2023.

Caracal Gold secures additional financing to expand Kilimapesa

Caracal Gold have secured an additional funding to expand the Kilimapesa Gold Mine in Kenya through a non-dilutive pre-paid gold purchase agreement.

A $3m financing facility has been made available to be drawn on before 31st December 2022 and add to a similar agreement for $10.5m announced in late November.

Caracal are now fully-funded to complete the expansion Kilimapesa Gold Mine with the aim of increasing both production and the resource.

“This second non-dilutive financing further strengthens Caracal’s cash position bringing the total raised in the last two weeks to US$13.5m,” said Robbie McCrae, CEO of Caracal Gold.

“Attracting these two new high-calibre partners, OCIM and Philoro, is testament to the vast potential Caracal offers as it focuses on becoming a +50,000oz per annum producer with +3moz in resources.

“We can now concentrate on the final push to deliver on our initial production target of 24,000oz per annum, whilst continuing to advance our regional exploration efforts in Kenya to ultimately build the life of mine and value potential. Alongside this, we are excited by the development opportunity Nyakafuru in Tanzania offers and look forward to progressing our targeted exploration programme to support a Preliminary Economic Assessment.”

Aquis weekly movers: Invinity Energy Systems continues its rise

Invinity Energy Systems (LON: IES) is the best performer for a second week on the back of an order for vanadium flow batteries from Taiwan. There was a further 26.4% rose to 45.5p.

Ananda Developments (LON: ANA) has published a general cannabis research round-up, including a pilot study that indicates that a cannabis-based spray can help alleviate cancer pain.  Ananda points to research that suggests that an individual’s genetics could predict the effects of cannabis. The share price improved by 8.42% to 0.515p.

Investment company Gunsynd (LON: GUN) net assets fell from £6.3m to £3.85m at the end of July 2022. There was a £1.95m reduction in the value of investments and the rest relates to the costs of running the company. The share price edged up by 2.41% to 0.425p.

==========

Fallers

Clean Invest Africa (LON: CIA) raised £155,000 at 0.5p a share – every two shares come with a warrant exercisable at 1.5p. The share price fell 15.4% to 0.275p. Clean Invest Africa is running short of cash. Subsidiary Coaltech is finding that lead times to securing sales and deals have been longer than expected. Certain creditors owed £2.5m have agreed to subordinate that debt to other trade creditors.

Shell company Greencare Capital (LON: GRE) is changing its investment strategy and name to MaxRS Ventures. Instead of seeking a cannabis-related acquisition, the company will try to identify opportunities that are undervalued or would benefit from being consolidated with other companies in its market. These would be technology type businesses and initially life sciences, crypto technology, impact investing and retail companies will be prioritised. The share price fell 12.3% to 25p. That valuation is still much higher than the interim net assets.

Guanajuato Silver Company Ltd (LON: GSVR) secured a $5m credit facility with Ocean Partners, which already provides a $5m facility. There will be a consolidated offtake agreement with Ocean Partners for 24 months to the end of December 2024. The share price declined by 1.82% to 27p.

Altona Rare Earths (LON: ANR) has completed drilling within budget at the Mozambique Monte Muambe rare earths project. This will enable a maiden mineral resource estimate in the first quarter of 2023. The share price slipped 1.69% to 7.25p.

AIM weekly movers: Petro Matad jumps on Mongolian progress

9

Petro Matad (LON: MATD) has gained access permission for exploration drilling on Block V in central Mongolia and the licence term has been extended. The development of the Heron-1 well continues and should be in production by the end of the year. Cash flow should finance further drilling. The share price jumped 70.3% to 3.15p.

The battery energy storage project in Uskmouth has received conditional planning consent and the SIMEC Atlantis Energy (LON: SAE) share price jumped by 30.4% to 1.825p, although it reached 2.325p at one point during Friday. Financial close for the project should be achieved by the first quarter of 2023.

Faron Pharmaceuticals (LON: FARN) has published a BEXMAB study update. The phase I/II study is for a combination of bexmarilimab in combination with standard of care in multiple haematological malignancies. An azacytidine-refractory acute myeloid leukemia (AML) patient achieved a complete remission. A second patient treatment shows signs of efficacy, and the remaining patients are stable. The treatment is well-tolerated. The share price improved by 27.4% to 360p.

Financial publisher and event organiser Bonhill (LON: BONH) has received an offer of £6.6m for its UK and Asia assets from a private UK company and this deal should complete in January. That would be worth 5.5p a share. There is also interest in the US business. There will be an EBITDA loss of £1.3m this year and there is around £300,000 in the bank. The share price rose by 26.1% to 7.25p.

In the six months to October 2022, MS International (LON: MSI) moved back into profit and net cash increased from £15.5m to £23.9m. The interim dividend is 14% higher at 2p a share. The defence and signage divisions are still loss making, but forgings and petrol station superstructures profit was increased significantly. The share price jumped 25.6% to 417p.

==========

Fallers

Utility infrastructure provider Fulcrum Utility Services (LON: FCRM) is raising up to £6m in loans from significant shareholders Bayford & Co and Harwood Capital. The annual interest rate is 20% and the loans can be convertible from April 2023. There is a 20% fee for early repayment and a non-utilisation fee of 6%. If the loan is converted into shares, then other investors will have an opportunity to buy new shares at the conversion price. The previous week, Fulcrum Utility Services received £1.5m from asset sales. The share price dived 54.4% to 1.55p.

Graphene technology developer Versarien (LON: VRS) is raising £1.85m at a heavily discounted share price of 10p. The share price slumped by 41.7% to 10.2p. Versarien will use the cash to commercialise its technology, particularly in the construction and leisure sectors. The UK government has agreed to delay repayments for a £5m loan until August 2025. There will be ten equal repayments in each subsequent quarter.

ReNeuron (LON: RENE) shares continue to fall in price following last week’s revelation that it tried to raise cash but found that market conditions meant that it could not be done at a suitable share price. Cost savings are being made by the exosomes technology company so that the existing cash can last until the fourth quarter of 2023. The share price declined a further 27.3% to 11.125p even though there was positive data about the advantages of induced pluripotent stem cells.

Edenville Energy (LON: EDL) is raising £400,000 at 7p a share. The share price dived 26.2% to 7.75p. It needs the cash because revenues from the Rukwa coal project in Tanzania have been lower than expected even though demand for the coal is strong. Changes have been made to management and efficiency is improving. The initial target is steady production of 3,000 tonnes of washed coal/month, rising to 4,000 tonnes/month. Edenville Energy is still waiting to recoup £180,000 in costs from Envirom Group due to an aborted acquisition. There is ongoing litigation.  

OptiBiotix Health (LON: OPTI) has raised £500,000 at 16p a share to invest in its direct-to-consumer products and US expansion. The share price of the microbiome-based products developer subsequently slumped 24.4% to 14.75p. Peterhouse has been reappointed as joint broker and it handled the placing.

Dekel Agri-Vision on course for full year profit

6

Cote d’Ivoire-based Dekel Agri-Vision (LON: DKL) continues to benefit from high crude palm oil prices and trading underpins the 2022 forecast.

The local crude palm oil price is near to its highs, although production is lower than in 2021. November’s average crude palm oil selling price is €1,043/ metric tonne – 9% higher than in November 2021.

Crude palm il extraction rates improved to 20.9% in November 2022, although production fell by more than two-fifths to 1,535 tonnes. Other producers in the country have also produced less.

Future

Commissioning of the cashew plant continues, and it should have a capacity of 10,000 tonnes a year. There is interest from buyers in Rotterdam and the quality is thought to be good.

Net debt is expected to be €30.3m and it should come down significantly in 2023. A small profit is forecast for 2022 and the initial contribution from cashews is expected to enable pre-tax profit to be more than €4m. Revenues could reach €50.4m with a €12m contribution from cashews.

At 3.3p, the shares are trading on eight times prospective 2023 earnings.